NCT04579588 Understanding Immunity to the Flu Vaccine in COVID-19 Patients
| NCT ID | NCT04579588 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Corona Virus Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 230 participants |
| Start Date | 2020-10-29 |
| Primary Completion | 2028-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 230 participants in total. It began in 2020-10-29 with a primary completion date of 2028-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19 symptoms. Adults and children (age 9 to 64) who had been diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.
Eligibility Criteria
Inclusion Criteria: * Age 9 through 64 years * Diagnosed with COVID-19 at least 2 months prior enrollment * Patients with or without obesity, diabetes, chronic fatigue and/or long term COVID-19 symptoms * Patients without COVID-19 diagnosis for controls Exclusion Criteria: * Received the influenza vaccine less than 4 months ago * Pregnant or lactating * Patients with special risks attendant to venipuncture * Use of immunomodulatory medications that may impact vaccine immune response per clinician's judgment * Contraindication to the flu vaccine * Immunodeficiency or autoimmune disease that may impact vaccine immune responses per clinician's judgement
Contact & Investigator
Sayantani Sindher, MD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT04579588 clinical trial?
This trial is open to participants of all sexes, aged 9 Years or older, up to 64 Years, studying Corona Virus Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04579588 currently recruiting?
Yes, NCT04579588 is actively recruiting participants. Contact the research team at snpcenterallergy_inquiry@stanford.edu for enrollment information.
Where is the NCT04579588 trial being conducted?
This trial is being conducted at Palo Alto, United States.
Who is sponsoring the NCT04579588 clinical trial?
NCT04579588 is sponsored by Stanford University. The principal investigator is Sayantani Sindher, MD at Stanford University. The trial plans to enroll 230 participants.